Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares have traded in a narrow range recently, moving roughly -1.5% over the trailing 30 days to about $28 per share.
• A dividend yield near 6% keeps the stock among the highest-yielding large-cap pharmaceuticals, backed by 56 consecutive years of payments.
• Management raised full-year 2026 revenue guidance after second-quarter results, citing strength in launched and acquired products outside the COVID franchise.
• The growth story centers on oncology (Seagen, Padcev), migraine (Biohaven), and an obesity portfolio anchored by monthly GLP-1 candidate berobenatide.
• The key overhang is a looming patent cliff, with Eliquis and Ibrance among major products set to face generic and biosimilar competition through the end of the decade.

Current Market Snapshot

Pfizer Inc. (PFE) shares have been relatively rangebound, slipping about 1.5% over the past 30 days to roughly $28 as of early October 2026. The stock has consolidated below its recent highs while holding well above its multi-year lows, reflecting a market that is balancing a defensive, high-yield profile against uncertainty over near-term revenue durability.

The equity continues to carry one of the highest dividend yields in the large-cap healthcare space, near 6%, which has made it a recurring fixture in value and income screens. At the same time, healthcare names have traded unevenly as investors weigh shifting rate expectations and a rotation toward higher-momentum sectors. Company-specific pipeline updates have kept Pfizer in focus relative to quieter peers, even when the broader group has softened.

Pfizer (PFE) Business Overview and Competitive Position

Pfizer is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, vaccines, immunology, rare disease, and internal medicine. Its scale, global commercial infrastructure, and extensive manufacturing network — a meaningful advantage for complex biologics and vaccines — underpin its competitive position.

The company has repositioned itself through a series of large acquisitions, most notably the Seagen antibody-drug conjugate (ADC) platform in oncology, the Biohaven migraine franchise led by Nurtec, and the Metsera portfolio in obesity and metabolic disease. Management has framed these deals as the foundation for the next wave of growth, with a stated goal of returning to high single-digit revenue growth beginning in 2029.

Investors follow Pfizer closely because it represents both a defensive income story and a pipeline turnaround narrative. The dividend, a quarterly payout of $0.43 per share, and the company's commitment to maintain and eventually grow it remain central to the investment case.

Recent Developments Driving PFE

Pfizer's second-quarter 2026 results provided a notable catalyst. Management raised full-year revenue guidance, citing stronger-than-expected performance across the non-COVID portfolio. Launched and acquired products — including Seagen and Biohaven assets — generated roughly $3.2 billion in revenue during the quarter and grew at a healthy double-digit operational rate, offering evidence that the rebuilt base is gaining traction.

In oncology, the U.S. Food and Drug Administration broadened Padcev's approved use into muscle-invasive bladder cancer, and the brand has continued to grow. On the obesity front, Pfizer has advanced berobenatide, a once-monthly GLP-1 candidate, through Phase 3 development, positioning the program against leaders such as Eli Lilly (LLY) and Novo Nordisk (NVO). Management has also highlighted a broad obesity pipeline that includes amylin-based combinations and an oral GLP-1 program.

Cost discipline remains a parallel theme, with a cost-realignment program targeting roughly $9.7 billion in net savings through 2029. On the analyst front, HSBC raised its price target on Pfizer to $30 from $28 in September while maintaining a Hold rating, with broader Street targets clustering in a wide range as views remain split between pipeline optimism and patent-cliff caution. Offsetting the positives, the company absorbed a multibillion-dollar noncash impairment in the June quarter after a late-stage lung cancer trial missed its primary endpoint, a reminder that pipeline execution remains the ceiling on the stock.

Trending AI Robots

For investors and traders looking to complement their own research with automated, data-driven tools, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant artificial-intelligence trading bots. Tickeron provides hundreds of AI-powered bots that trade thousands of tickers, but only the top-performing and most relevant strategies are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving users a way to explore approaches that align with different risk profiles and holding periods. The page is designed as a discovery tool, offering a neutral snapshot of which algorithms are currently drawing attention rather than a specific recommendation.

2026 Outlook and What Investors Should Watch

Looking ahead, Pfizer's path will hinge on execution across three fronts. First, investors should monitor the pace at which newer oncology, migraine, and internal-medicine products offset revenue lost to patent expiries — particularly Eliquis and Ibrance, two of the company's largest franchises. Second, the obesity program is a key swing factor, with berobenatide Phase 3 data and a potential approval later in the decade acting as long-dated catalysts against the established GLP-1 leaders.

Third, cost savings, deleveraging, and dividend sustainability will remain in focus. Management has signaled that debt reduction takes priority over large-scale dealmaking, and free cash flow coverage of the dividend is a metric income investors will continue to scrutinize. Macroeconomic factors, including interest-rate expectations and drug-pricing policy developments, may also influence sentiment. These are factors to monitor rather than a basis for any specific forecast, as Pfizer's valuation continues to reflect both its generous yield and the uncertainty surrounding its post-patent-cliff growth trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations